Replacing this historically judgment-intensive work with LLMs is quickly becoming one of the most effective wedge strategies when building AI-native applications. Why is that the case?
Data recently posted on a federal website shows the cyberattack earlier this year at a UnitedHealth Group subsidiary affected 100 million patients — apparently a record in the U.S. The tally roughly matches the scope previously described by company CEO Andrew Witty, who suggested during congressional testimony in May that data for 1 in 3 Americans could be affected by the hack.
The FDA has named Dr. Michelle Tarver, an agency veteran, the new director of the medical device division. Dr. Tarver will face a slate of pressing tasks, that include addressing calls to strengthen standards to protect the public from issues like racial bias in AI software and hastily authorized and faulty cardiac devices, like external defibrillators.
A coalition of 12 Philadelphia-area health systems announced Monday that its members have abandoned the use of race adjustments in four clinical tools commonly used to guide care, a move that health leaders say will improve treatment and prevent delays in diagnosis for Black, Hispanic, and Asian patients. The decision marks one of the largest and broadest efforts to date to remove race from widely used clinical algorithms.
The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem regulators and industry need to work on together.
Lawmakers on both sides of the aisle in the House and Senate are calling for COVID-era flexibilities on telemedicine services to be extended to ensure access to “necessary and life-saving treatments,” and are speaking out against a proposed rule reportedly being advanced by the DEA that would limit telemedicine prescribing.